Prospective, double-blind, randomized, two-part, placebo-controlled, cross-over study investigating the effect of sugammadex on anti-Xa anticoagulant activity of enoxaparin and the activated partial thromboplastin time (APTT) of unfractionated heparin (UFH)

Trial Profile

Prospective, double-blind, randomized, two-part, placebo-controlled, cross-over study investigating the effect of sugammadex on anti-Xa anticoagulant activity of enoxaparin and the activated partial thromboplastin time (APTT) of unfractionated heparin (UFH)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Dec 2015

At a glance

  • Drugs Sugammadex (Primary) ; Enoxaparin sodium; Heparin
  • Indications Blood coagulation disorders
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 30 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top